Introduction: Atrial remodelling, leading to atrial fibrillation (AF), is mediated by the renin-angiotensin-aldosterone system. Methods: Mild hypertensive outpatients (systolic/diastolic blood pressure 140-159/90-99 mmHg) in sinus rhythm who had experienced ≥ 1 electrocardiogram (ECG)-documented AF episode in the previous six months received randomly telmisartan 80 mg/day or carvedilol 25 mg/day. Blood pressure and 24-hour ECG were monitored monthly for one year; patients were asked to report symptomatic AF episodes and to undergo an ECG as early as possible. Results: One hundred and thirty-two patients completed the study (telmisartan, n=70; carvedilol, n=62). Significantly fewer AF episodes were reported with telmisartan versus carvedilol (14.3% vs. 37.1%; p<0.003). Left atrial diameter, assessed by echocardiography, was similar with telmisartan and carvedilol (3.4±2.3 cm vs. 3.6±2.4 cm). At study end, both regimes significantly reduced mean left ventricular mass index, but the reduction obtained with telmisartan was significantly greater than with carvedilol (117.8±10.7 vs. 124.7±14.5; p<0.0001). Mean blood pressure values were not significantly different between the groups (telmisartan 154/97 to 123/75 mmHg; p<0.001; carvedilol 153/94 to 125/78 mmHg; p<0.001). Conclusions: Telmisartan was significantly more effective than carvedilol in preventing recurrent AF episodes in hypertensive AF patients, despite a similar lowering of blood pressure.
Introduction
Atrial fibrillation (AF) is the most common cardiac arrhythmia seen in clinical practice 1, 2 and is associated with an increased long-term risk of stroke, heart failure and allcause mortality. [3] [4] [5] AF occurs more frequently in patients with uncontrolled hypertension, [3] [4] [5] with some data suggesting that the risk is 1.42 times higher in hypertensive subjects than in their normotensive counterparts. 6 As hypertension is highly prevalent in the general population, it independently accounts for more cases of AF than any other risk factor. 2 Other independent risk factors for newonset AF include increasing age, left ventricular mass (LVM) and atrial size. 7 An increased left atrial size has also been shown to pre-dispose patients to development of chronic AF. 7 Progressive structural changes of the atria, resulting in atrial dilation and loss of transport function, are a feature of AF. 8, 9 Atrial stretch induced by increased atrial pressure may be involved in the initiation and pathogenesis of AF through shortening of the refractory period and lengthening of the intra-atrial conduction time. 10, 11 The vasoconstrictor A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients peptide, angiotensin II, has been recognized as a key element in atrial remodelling in association with AF. Angiotensin II acts via the angiotensin type 1 (AT 1 ) and angiotensin type 2 (AT 2 ) receptors in the renin-angiotensin-aldosterone system (RAAS) cascade, a system that is involved in many events that could promote AF. The AT 1 receptor mediates the deleterious effects of angiotensin II, including elevated blood pressure (BP), increased intracavitary atrial pressure, coronary atherosclerosis, increased reactive oxygen substances and cardiac and vascular remodelling. 12 A previous study demonstrated that the atrial expression of angiotensin-converting enzyme (ACE) is increased in patients with AF, possibly leading to angiotensin II-dependent progressive myocardial fibrosis. 13 Angiotensin II is also thought to promote myocyte cell growth, and the subsequent aldosterone secretion may increase collagen content (via reduced collagenase activity) and stimulate the proliferation of cardiac fibroblasts. 14 Angiotensin II receptor blockers (ARBs) target the RAAS by binding to AT 1 receptors. This mode of action allows available angiotensin II to stimulate AT 2 receptors, which may provide target-organ protection. 15 In clinical studies, blockade of the RAAS with antihypertensive therapies, such as ARBs, prevented new-onset AF and also prevented recurrence after cardioversion of AF. [16] [17] [18] [19] There are different clinical scenarios involving prevention of AF in the hypertensive patient (i.e. those who have not had any previous episodes of AF, and those with paroxysmal or persistent AF who either do not need any antiarrhythmic therapy, or those with persistent AF who do require anti-arrhythmic therapy to maintain sinus rhythm following cardioversion). [16] [17] [18] [19] Telmisartan has the longest half-life of any ARB (approximately 24 hours) 20 and has been shown to reduce left ventricular hypertrophy (LVH) in clinical studies of hypertensive patients, [21] [22] [23] [24] as well as in the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) and Telmisartan Randomized AssessmeNt Study in ACE-I iNtolerant subjects with cardiovascular Disease (TRANSCEND) cardiovascular (CV) outcomes, although no reduction in new-onset AF was found. [25] [26] [27] The purpose of the present study was to assess the efficacy of an antihypertensive therapeutic dose of telmisartan (80 mg once daily) as compared with that of the β-blocker carvedilol (25 mg once daily), which has been shown to have clinically important anti-arrhythmic properties, [28] [29] [30] [31] [32] for the prevention of AF recurrence in a population of hypertensive patients with a recent history of AF and who were in sinus rhythm and who did not require anti-arrhythmic therapy. The original study design was conceived in March 2005 and further amended following discussions with the participating centres and investigators prior to study initiation. The trial was not registered at any public registry prior to initiation, as there were no such requirements from the Italian authorities at the time. The trial was approved by local ethics boards, and was compliant with the Declaration of Helsinki and Good Clinical Practice guidelines. Written informed consent was obtained from the patients prior to enrolment.
Methods
Patients aged ≥ 18 years with mild hypertension (systolic BP (SBP) 140-159 mmHg and/or diastolic BP (DBP) 90-99 mmHg measured using a manual cuff mercury sphygmomanometer at the end of the one-week wash-out period) and an optimal two-dimensional echocardiography acoustic window were eligible for inclusion if they displayed sinus rhythm and had one or more electrocardiography (ECG)-documented episodes of AF in the previous six months (converted either spontaneously or pharmacologically) and a left atrial diameter < 6 cm (as determined by two-dimensional echocardiography). We defined AF paroxysmal when it lasts seven days or less; when sustained beyond seven days, AF is designated persistent. Termination with pharmacological therapy or direct-current cardioversion does not change the designation. First-detected AF may be either paroxysmal or persistent AF. [33] [34] [35] [36] Exclusion criteria included previous myocardial infarction, previous stroke, renal failure, chronic severe liver disease or congestive heart failure and left ventricular ejection fraction < 50%, as determined by two-dimensional echocardiography. In addition, women who were pregnant or breastfeeding were excluded.
Eligibility was established after a one-week placebo wash-out period for antihypertensive therapy. Eligible patients were then randomized 1:1 to receive telmisartan 80 mg once daily or carvedilol 25 mg once daily for a total of 48 weeks. These are the maximum dosages approved for the treatment of hypertension in Italy, where the study was conducted. Study medication was to be taken in the early morning hours. No other antihypertensive treatments were allowed for the duration of the study and any patient failing to respond sufficiently to treatment (SBP/DBP > 140/90 mmHg) was withdrawn from the study. BP measurements and 24-hour ECG were recorded every four weeks; in addition to palpitations and new symptoms, patients were asked to report any episodes of symptomatic AF and to have ECG evaluations performed as soon as possible. Standard blood tests, clinic BP measurement, 24-hour ECG and two-and three-dimensional echocardiography were performed at baseline and after the end of the 48-week active treatment period. Adverse events were monitored throughout by clinical examinations and cuff BP measurements carried out at weeks 6, 18 and 32.
Preliminary assessment of an optimal two-dimensional echocardiography acoustic window on a four-grade scale (poor, sufficient, good, optimal) was performed using an Agilent Sonos 5500 ® echocardiograph or iE33 (Philips Medical Systems, Eindhoven, The Netherlands), or ATL 5500 (Philips Medical Systems), or Vivid 7 (GE Healthcare, USA). All baseline and end-of-treatment three-dimensional echocardiographic assessments (end-diastolic) were performed at the Three-Dimensional Echocardiography Laboratory, Division of Cardiology, San Gennaro Hospital, Naples, Italy, and at La Sapienza University, Rome, Italy, by transthoracic echocardiography TomTec ® software, with the LVM being calculated by disc summation. The left ventricle was divided into multiple equidistant, parallel, transverse, short-axis cutting planes (7 mm) from the atrioventricular groove to the apex; the papillary muscles were not included. On each of these slices, the endocardium and the epicardium were traced and the area between them was measured by the computer, as was the volume of each slice. The total left ventricular volume was obtained by adding the values of the individual slices, and the total myocardial mass was derived by multiplying the myocardial wall volume (ml) by the tissue density of the heart (g/ml). Each echocardiographic evaluation was independently reviewed by two observers who were blinded to treatment.
Power calculations showed that 62 patients in each group and a total of 93 AF events would be required to detect the difference between a group control proportion of 0.300 and a group treatment of 0.100 (a constant hazard ratio of 0.523) with a 0.05 significance level in a two-sided log-rank test for equality of survival curves and 87% power.
All data are expressed as mean ± standard deviation (SD). Statistical analysis was performed within treatment groups using a t-test for unpaired data with a p-value <0.05 considered to be statistically significant. A χ 2 test was used to assess the difference between categorical variables. The time to first AF recurrence was analysed using the Kaplan-Meier method and compared with the log-rank test, with a p-value < 0.05 considered to be statistically significant.
Random samples of 20 echocardiograms were evaluated by two independent readers to assess inter-reader consistency, and each reader re-evaluated a random sample of echocardiograms to evaluate intra-reader consistency. Kappa statistic was used to determine inter-and intrareader variability in the assessment of echocardiographic parameters.
Results
A total of 154 patients with mild hypertension were enrolled, of which 132 completed the study. Of the enrolled patients, 22 patients withdrew prior to completion: 13 patients because DBP remained > 90 mmHg (six in the telmisartan group and seven in the carvedilol group); two patients due to dizziness; one patient due to cough; and six patients due to other causes. There were no statistically significant differences between the treatment groups in terms of baseline characteristics (Table 1) . Enrolled patients were in sinus rhythm and hence, in accordance with Italian and international treatment guidelines, [33] [34] [35] [36] did not receive antiarrhythmic, antiplatelet or anticoagulant therapy to prevent AF recurrences. Prior to randomization, the use of antihypertensive drugs was as follows: ARBs (n=30); ACE inhibitors (ACEIs) (n=34); thiazide diuretics (n=12); indapamide (n=12); calcium antagonists (n=10); 46 patients did not receive any antihypertensive drugs.
In terms of co-morbidities, the majority of the enrolled patients (90/132) had hyperlipidaemia, which was treated with statins and/or recommendations for lifestyle changes (improved diet/increased physical activity). There was no statistical difference in the number of patients assuming statins between the two groups. Twenty patients suffered from arthritis and received anti-inflammatory drugs (with treatment periods lasting no longer than 15 days). Two patients suffered asymptomatic gallstones (with only mild elevation of transaminases and bilirubin and with normal indices of liver function) that were pharmacologically treated. Ten male patients suffered from chronic obstructive pulmonary disease and were treated with (cyclic periods) of β-stimulants and/or aerosol therapy with cortisone and mucolytic agents (seven patients in the telmisartan group and three patients in the carvedilol group). Two patients had bronchial asthma. Overall, 30% of the male patients and 20% of the females were smokers.
No diabetic patients were included in our study. All patients had a normal renal function, with the exception of three patients who had a mild elevation of creatinine (1.4-1.5 mg/dl); in two of these three patients (one in the telmisartan group, one in the carvedilol group) the creatinine levels decreased at the end of the study; in the third patient (carvedilol group) the creatinine levels remained unchanged throughout the study period. The weight and height of patients in each treatment group were similar. Of the enrolled patients, 107/154 (69%) with a LVM index (LVMI) of > 130 g/m 2 body surface in males and > 110 g/m 2 in females were classified as having LVH according to international guidelines. 37 Treatment with telmisartan 80 mg/day or carvedilol 25 mg/day resulted in significant reductions in LVM index after 12 months. Telmisartan reduced mean LVM index from 137.8±10.6 g/ m 2 at baseline to 117.8±10.7 g/m 2 at study end (p≤0.0001), and carvedilol reduced LVM index from 134.7±15.2 g/m 2 at baseline to 124.7±14.5 g/m 2 at study end (p<0.0001). Furthermore, after 12 months, treatment with telmisartan 80 mg/day reduced the mean LVM index to a significantly greater extent than treatment with carvedilol 25 mg/day (p<0.0001) ( Table 2 and Figure 1 ). Moreover, treatment with telmisartan and carvedilol significantly reduced the mean left atrial diameter (as assessed by echocardiogram) compared with baseline values (from 4.4±3.0 cm to 3.4±2.3 cm with telmisartan (p<0.001); and from 3.9±2.9 cm to 3.6±2.4 cm with carvedilol (p<0.001)). The difference between the two treatment groups was not statistically significant ( Table 2 ).
The inter-and intra-reader variability in echocardiographic assessment was low (κ>0.75).
Most patients had one or two episodes of AF in the six months prior to the study, with only five patients reporting three to four episodes ( Table 1) .
Most of the patients enrolled had paroxysmal AF; there was no difference between the groups in the type of AF (number of episodes of AF (paroxysmal/persistent): telmisartan group, 77/18; carvedilol group, 68/14). In paroxysmal AF, triggered activity or firing plays a dominant role in the arrhythmogenesis. On the other hand, in persistent AF, substrate is more important; previous studies suggest that beta-blockers are more effective on triggered activity or on firing and that ARBs, ACEIs or statins are considered to be more effective on substrate. In our study we have too few cases to investigate this; furthermore we do not have a statistically significant difference in the distribution of paroxysmal and persistent AF in the two groups.
We do not have exact documented data on AF duration in all patients with persistent AF, only in 15 patients treated with telmisartan (range 7-20 days, mean 12.6 ± 3.47) and in 12 patients treated with carvedilol (range 8-18 days, mean 12.8 ± 3.7). There was no statistically significant difference between the two groups. According to guidelines, the duration of AF is considered a predictor of recurrence when it goes beyond three months; in our study no patient had AF longer than three months. In five patients we did not have documented data, only the clinical history; the patients reported that the AF terminated in 12, 16 and 13 days in the telmisartan group and in 18 and 16 days in carvedilol group.
During the 12-month study period, significantly fewer patients in the telmisartan 80 mg/day group experienced episodes of documented symptomatic AF; only 14.3% (10/70) of patients reported episodes of AF compared with 37.1% (23/62) of those in the carvedilol group (p<0.003; χ 2 test). Throughout the study, a greater percentage of patients receiving telmisartan 80 mg/day remained free from recurrences of AF compared with those who received carvedilol 25 mg/day ( Figure 2 ). In addition, in patients in the telmisartan group the time to first recurrence of AF was longer compared with those in the carvedilol group. In the telmisartan group the time to first recurrence of AF was 62.5±41.6 days (range 20-142 days) while in the carvedilol group it was 118.1±100.1 days (range 15-320 days).
There were significant reductions in the mean BP from baseline in patients in both the telmisartan 80 mg/day and carvedilol 25 mg/day groups: telmisartan reduced mean SBP/DBP from 154/97 mmHg at baseline to 123/75 mmHg at 12 months (p<0.001), and carvedilol reduced mean SBP/ DBP from 153/94 mmHg at baseline to 125/78 mmHg at 12 months (p<0.001). The difference between the two treatment groups was not statistically significant ( Table 2) .
Treatment with telmisartan 80 mg/day or carvedilol 25 mg/day was generally well tolerated, with similar incidences of mostly mild-to-moderate adverse events commonly associated with these two classes of drugs.
Discussion
The incidence of AF is increased in patients with uncontrolled hypertension, [3] [4] [5] and the importance of optimal BP lowering is well recognized. Antihypertensive treatments reduce the incidence of CV morbidity and mortality, as well as reducing the occurrence of AF. In our present study, designed to assess the efficacy of two antihypertensive treatments for the prevention of AF, we found that telmisartan was significantly (p<0.003) more effective than carvedilol in preventing asymptomatic and/or symptomatic recurrent episodes of AF in hypertensive patients with a recent history of AF who did not require anti-arrhythmic therapy.
The difference between the treatment groups, in terms of the prevention of AF recurrences (14% in the telmisartan group vs. 37% in the carvedilol group), was related to a significant reduction in BP, LVMI and left atrial size but also other factors are implicated in the pathogenesis. We observed a greater LVM reduction in the telmisartan group. However, the mean BP at the end of the study period was numerically lower in the telmisartan group (123/75 mmHg) compared with the carvedilol group (125/78 mmHg). It is possible that antihypertensive therapy may decrease atrial pressure and thereby impact on AF. However, the results of our study indicate that the greater effect of telmisartan in the prevention of AF recurrences is independent of BP lowering. Furthermore, in patients in the telmisartan group, AF recurrences were delayed compared with those in the carvedilol group. It is likely that improved reductions of AF episodes, as observed with telmisartan, may have a positive impact of the long-term risk of CV adverse events such as stroke, heart failure and all-cause mortality.
As a consequence of the study methodology we have to consider the following study limitations: with 24-hour ECGs being performed every four weeks, any asymptomatic episodes of AF recurrences that converted spontaneously between scheduled follow-up visits would not have been recorded; we did not use seven day Holter ECG monitoring, which would have helped in better detection of asymptomatic or poor symptomatic episodes of AF in the patients.
We have also to consider that the patients with carvedilol may be less symptomatic because of rate control effect, and AF recurrence might have been underestimated.
The majority of patients in our study had one or two episodes of AF at baseline, with only three patients with three previous AF episodes (two in the telmisartan group and one in the carvedilol group) and two patients with four previous AF episodes (one in each group). With the low number of patients with more than three or four previous AF episodes in our study, it is difficult to speculate whether this could influence results. A further study involving patients with a higher number of previous AF episodes at baseline would be required to establish whether treatment effect is influenced by frequency of previous events.
Previous studies reporting AF duration (how long lasting) and paroxysmal AF versus persistent AF are more associated with AF recurrence and atrial remodelling than number of AF episodes. In our study most patients had paroxysmal AF; because we had few episodes of persistence and few episodes of different types of AF we could not assess the extent of paroxysmal and persistent AF and AF duration in predicting further recurrence. Further studies are required to better elucidate the evolution of different types of AF and AF duration. In our study no patient had AF for longer than three months, the period that is considered a predictor of recurrence. [33] [34] [35] [36] In the clinical arena and in our experience patients often do not require anti-arrhythmic therapy to prevent recurrent AF. According to the guidelines, before antiarrhythmic drug therapy is initiated, treatment of precipitating or reversible causes of AF is recommended. Our patients did not require antiarrhythmic drug therapy because we treated their hypertension; furthermore, the episodes of AF were not frequent and did not give troublesome symptoms; moreover, our patients were not of advanced age and did not suffer left ventricular systolic dysfunction or heart failure. In this context the use of an antihypertensive drug, associated with a lower incidence of recurrence, is very useful.
Our study also demonstrated that telmisartan reduced the mean LVM index to a significantly greater extent than carvedilol (p<0.0001).
In the Valsartan Heart Failure Trial (Val-HeFT), adding treatment with an ARB to existing treatment for heart failure (including ACE inhibitors in 92.5% of patients) reduced the incidence of AF by 37%. 17 However, in the LIFE trial, 18 losartan and atenolol had similar BP-lowering capabilities, but losartan prevented AF to a greater extent. Thus, it would appear that BP lowering cannot fully explain the beneficial effect seen in terms of a reduction in new-onset AF.
One of the world's largest CV outcomes studies, the ONTARGET trial, assessed the effect of RAAS blockade on AF as a secondary outcome in a broad range of patients at high risk for vascular events. 26 In this study, there was no significant difference in the incidence of new-onset AF with telmisartan (6.7%) compared with the ACE inhibitor ramipril (6.9%; relative risk (RR) 0.97; 95% confidence interval (CI) 0.86-1.09), or with ramipril versus a combination of telmisartan and ramipril (6.5%; RR 0.96; 95% CI 0.85-1.07). 26 However, ONTARGET was not designed to assess the antihypertensive effects of the two agents or their combination on outcomes (only 69% of patients had hypertension and it was intended that patients' BP be managed with the best standard of care).
There are many potential mechanisms by which inhibition of the RAAS may reduce the incidence of AF independently of BP lowering per se by interfering favourably with the cardiac electrical and structural remodelling process in hypertensive patients, and further research is required to clarify those mechanisms. A meta-analysis by Healey et al. of 11 randomized trials investigating the effect of ACEIs and/or ARBs on AF found that, although both drug classes appeared to be effective in preventing AF (a 28% and 29% reduction, respectively), the effect seemed to be most clearly seen in patients with left ventricular dysfunction or LVH, including those treated for hypertension. 16 This suggests that the benefit may be related to an improvement in cardiac haemodynamics and a reduction in left ventricular and left atrial wall stress. 16 Blockade of the RAAS plays an important role in AF, not only at the ventricular level by reducing the LVM, but also as a mediator of atrial remodelling. A telmisartan-based treatment was shown to significantly improve the sympathovagal balance, increasing parasympathetic activity and cardiac electrical stability, reducing the heterogeneity of ventricular repolarization (a significant reduction of QT and QTc dispersion) in hypertensive subjects. 38 Moreover, telmisartan has beneficial effects also on atrial conduction times, in particular on the prolongation of P-wave times and increase of P-wave dispersion, which have shown to be independent predictors of AF. In a recent randomized clinical study, telmisartan showed a much greater lowering effect on P-wave dispersion and P-maximum values than ramipril. 39 In conclusion, our study shows that, over the course of 12 months, telmisartan was significantly more effective than carvedilol in preventing recurrent AF episodes in hypertensive patients not requiring antiarrhythmic drug therapy, despite a similar lowering of BP. Further studies are required to establish the longer-term benefits of treatment with telmisartan on AF events.
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